ClinicalTrials.gg

Program

tegtociclib

Also written as “PF-07220060 + PF-07104091 combination dose escalation”, “PF-07104091 + PF-07220060 + fulvestrant dose expansion” and “PF-07104091 + PF-07220060 + letrozole dose expansion”.

In Pfizer's pipeline, CDK2 inhibitor. Its studies are mostly in Breast Neoplasms · Small Cell Lung Carcinoma, led by Pfizer.

Furthest: phase 2, since Aug 21, 20204 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer42 open or runningphase 2since Aug 21, 2020Aug 21, 2020Dec 31, 2026phase 2 · NCT04553133
  • Named in Pfizer’s own pipeline as tegtociclib PF-07104091, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2020First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT04553133 · 157 enrolled · United States, Argentina, Bulgaria and more
  2. Feb 21, 2022Phase 2 study in Breast NeoplasmsNCT05262400 · 235 enrolled · United States, Argentina, Brazil and more
  3. Jun 9, 2022Phase 1 study in HealthyNCT05431153 · 30 enrolled · United States
  4. Jul 1, 2025Phase 1 study in Healthy AdultsNCT07127770 · 9 enrolled · Netherlands

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT04553133
  2. Feb 26, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05262400

TargetBeta

“CDK2 inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tegtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tum…”NCIt, read by Claude
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule

Other programs on CDK2

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
CDK2 Inhibitor INCB123667ruleIncytephase 37
vustanaciclibregor-pharmaceuticals-incphase 23
CDK2 Inhibitor AVZO-021ruleavenzo-therapeutics-incphase 22
CDK2 Inhibitor ECI830Novartisphase 21
CDK2 Degrader BG-75098ruleBeOne Medicinesphase 11
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
ZE94-0605ruleeilean-therapeuticsphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07127770Healthy Adults · Netherlands1CompletedOct 8, 20259
NCT05431153Healthy · United States1CompletedOct 17, 202230
NCT05262400Breast Neoplasms · United States, Argentina, Brazil and more2Active, not recruitingFeb 26, 2027235
NCT04553133Small Cell Lung Carcinoma · United States, Argentina, Bulgaria and more2Active, not recruitingDec 31, 2026157

How it is read

Names in the registry

  • “PF-07220060 + PF-07104091 combination dose escalation”, 8 entries
  • “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
  • “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry
  • “PF-07104091 monotherapy dose escalation”, 1 entry
  • “PF-07104091 + palbociclib + fulvestrant”, 1 entry

Codes read as this program: PF07104091.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.